MedTrace Logo

A Study Evaluating the Pharmacokinetics of Three QRL-101 Formulations in Healthy Participants

NCT06877624 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2025-08-26

No results posted yet for this study

Summary

This study aims to evaluate the pharmacokinetics of three QRL-101 formulations in a fasted condition or in the presence of a high-fat meal in healthy participants.

Conditions

  • Healthy Volunteers

Interventions

DRUG

QRL-101

This cross-over design study will evaluate three formulations (Formulations 1, 2, and 3) of QRL-101, beginning in a fasted condition before moving to a fed cross-over design.

Sponsors & Collaborators

  • QurAlis Corporation

    lead INDUSTRY

Principal Investigators

  • Salah Hadi, MD · ICON plc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-01-10
Primary Completion
2025-05-15
Completion
2025-05-15

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06877624 on ClinicalTrials.gov